Publications by authors named "Libor Gabalec"

Claim this Profile
U
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
David T Rubin, Marc Bradette, Libor Gabalec, Daniela Dobru, Juan Márquez

J Crohns Colitis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.
Yan Yiannakou, Hubert Piessevaux, Michel Bouchoucha, Ingolf Schiefke, Rafal Filip, Libor Gabalec

Am J Gastroenterol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Volker Gross, Ivan Bunganic, Elena A Belousova, Tatyana L Mikhailova, Limas Kupcinskas, Libor Gabalec

J Crohns Colitis· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Andreas Tromm, Ivan Bunganič, Eva Tomsová, Zsolt Tulassay, Milan Lukáš, Libor Gabalec

Gastroenterology· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis